Phibro Animal Health Corporation $PAHC Shares Sold by American Century Companies Inc.

Key Points

• American Century Companies Inc. decreased its stake in Phibro Animal Health Corporation by 32.9% in the first quarter, selling 209,232 shares, which reduced their ownership to about 1.05% of the company.
• Multiple hedge funds have adjusted their stakes in Phibro, with GAMMA Investing LLC increasing its holdings by 2,011.4% and LPL Financial LLC increasing by 46.8% in the first quarter.
• Phibro recently announced a quarterly dividend of $0.12 per share, with an annualized yield of 1.5%, set to be paid on September 24th to investors of record.

American Century Companies Inc. decreased its position in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 32.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 426,367 shares of the company's stock after selling 209,232 shares during the quarter. American Century Companies Inc. owned 1.05% of Phibro Animal Health worth $9,107,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Phibro Animal Health in the fourth quarter valued at $29,000. National Bank of Canada FI acquired a new position in Phibro Animal Health in the first quarter valued at $30,000. Lazard Asset Management LLC boosted its stake in Phibro Animal Health by 2,739.7% in the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock valued at $34,000 after acquiring an additional 1,589 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Phibro Animal Health in the fourth quarter valued at $69,000. Finally, Virtus Fund Advisers LLC acquired a new position in Phibro Animal Health in the fourth quarter valued at $69,000. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Price Performance

Shares of PAHC traded down $1.39 during mid-day trading on Monday, reaching $37.07. 644,926 shares of the company's stock were exchanged, compared to its average volume of 323,934. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. The company has a 50-day simple moving average of $29.59 and a two-hundred day simple moving average of $24.53. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $38.83. The company has a market cap of $1.50 billion, a price-to-earnings ratio of 31.42, a PEG ratio of 0.54 and a beta of 0.88.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The company had revenue of $378.70 million for the quarter, compared to analyst estimates of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, sell-side analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. Phibro Animal Health's payout ratio is 40.68%.

Wall Street Analysts Forecast Growth

PAHC has been the subject of several recent research reports. Zacks Research downgraded shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday. BNP Paribas Exane upgraded shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price for the company in a research note on Monday, June 16th. BNP Paribas upgraded shares of Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. Bank of America increased their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the stock an "underperform" rating in a research note on Friday. Finally, Wall Street Zen raised shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and a consensus price target of $28.40.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.